AJR ARRS PQI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wang, J.
Right arrow Articles by Song, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, J.
Right arrow Articles by Song, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.08.1367
AJR 2009; 193:1090-1096
© American Roentgen Ray Society


Original Research

Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Perfusion CT Evaluation of Chemotherapy and Radiation Therapy

Jianwei Wang1, Ning Wu1, Matthew D. Cham2 and Ying Song1

1 Department of Diagnostic Radiology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, PO Box 2258, 17 Panjiayuan Nanli, Beijing 100021, China.
2 Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY.

OBJECTIVE. The objectives of this study were to prospectively evaluate changes in tumor perfusion after chemoradiation therapy and to investigate the feasibility of perfusion CT for prediction of early tumor response and prognosis of non–small cell lung cancer.

SUBJECTS AND METHODS. Perfusion CT was performed on an MDCT scanner with 50 mL of iodinated contrast material injected at 4 mL/s. The quality of each functional map was rated from 0 to 3 for 123 patients with confirmed lung cancer. A subset of images was independently reviewed by two radiologists to measure interobserver and intraobserver variability. Perfusion parameters and tumor response were assessed for 35 patients with non–small cell lung cancer who underwent chemoradiation therapy. Progression-free survival and overall survival were analyzed for 22 patients who underwent repeated perfusion CT after therapy.

RESULTS. Image quality was graded 2 (moderate) or 3 (good) in 68.2% of cases. High interobserver and intraobserver correlations of perfusion parameters were found on qualified images. The patients who responded to chemoradiation therapy had significantly greater blood flow (p = 0.023) than patients who did not respond. The median progression-free survival period of the patients with an increased permeability–surface area product was 4.7 months, significantly lower than the median progression-free survival period of 19.0 months among patients with a decreased permeability–surface area product (p < 0.001). The median overall survival period was 10.6 months for the group with an increased permeability–surface area product, significantly lower than the 19.3 months for the group with a decreased permeability–surface area product (p = 0.004).

CONCLUSION. Non–small cell lung cancer with higher perfusion is more sensitive to chemoradiation therapy than that with lower perfusion. After chemoradiation therapy, findings at perfusion CT are a significant predictor of early tumor response and overall survival among patients with non–small cell lung cancer.

Keywords: chemotherapy • lung neoplasms • perfusion CT • prognosis • radiation therapy


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Roentgen Ray Society.